NCT00082641View on ClinicalTrials.gov

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 1, 2004

Primary Completion Date

May 1, 2009

Study Completion Date

January 1, 2018

Conditions
Breast Cancer
Interventions
BIOLOGICAL

autologous dendritic cell-adenovirus p53 vaccine

Given subcutaneously on one of two schedules

Trial Locations (1)

68198-6805

Eppley Cancer Center, University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

University of Nebraska

OTHER

NCT00082641 - Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer | Biotech Hunter | Biotech Hunter